RaQualia Pharma Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	3,049	3,107	1,901	2,918	2,776	1,107
Revenue Growth (YoY)	9.87%	63.44%	-34.85%	5.12%	150.77%	-34.96%
Cost of Revenue	776.13	625	245	231	321	138
Gross Profit	2,273	2,482	1,656	2,687	2,455	969
Selling, General & Admin	1,118	782	615	566	615	518
Research & Development	1,686	1,703	1,372	1,248	1,127	932
Amortization of Goodwill & Intangibles	-	203	-	-	-	-
Operating Expenses	2,804	2,695	1,993	1,820	1,747	1,455
Operating Income	-530.91	-213	-337	867	708	-486
Interest Expense	-58.43	-42	-7	-6	-1	-
Interest & Investment Income	17.46	8	9	13	22	31
Currency Exchange Gain (Loss)	2.21	38	52	43	145	-75
Other Non Operating Income (Expenses)	12.55	-130	11	-17	-1	3
EBT Excluding Unusual Items	-557.13	-339	-272	900	873	-527
Gain (Loss) on Sale of Investments	-	4	-	-35	16	2
Asset Writedown	-	-23	-22	3	-10	-2
Other Unusual Items	-	-	-	-18	-	-
Pretax Income	-557.13	-358	-294	850	879	-527
Income Tax Expense	167	137	29	127	124	79
Net Income	-724.12	-495	-323	723	755	-606
Net Income to Common	-724.12	-495	-323	723	755	-606
Net Income Growth	-	-	-	-4.24%	-	-
Shares Outstanding (Basic)	23	22	22	21	21	21
Shares Outstanding (Diluted)	23	22	22	21	21	21
Shares Change (YoY)	6.29%	0.16%	2.97%	0.05%	0.10%	1.62%
EPS (Basic)	-31.50	-22.87	-14.95	34.48	36.03	-28.93
EPS (Diluted)	-31.50	-22.87	-14.95	34.47	36.03	-28.93
EPS Growth	-	-	-	-4.34%	-	-
Free Cash Flow	-284	84	-923	1,449	274	-438
Free Cash Flow Per Share	-12.35	3.88	-42.72	69.06	13.06	-20.91
Gross Margin	74.55%	79.88%	87.11%	92.08%	88.44%	87.53%
Operating Margin	-17.41%	-6.86%	-17.73%	29.71%	25.50%	-43.90%
Profit Margin	-23.75%	-15.93%	-16.99%	24.78%	27.20%	-54.74%
Free Cash Flow Margin	-9.31%	2.70%	-48.55%	49.66%	9.87%	-39.57%
EBITDA	-51.45	188	-162	1,014	849	-362
EBITDA Margin	-1.69%	6.05%	-8.52%	34.75%	30.58%	-32.70%
D&A For EBITDA	479.46	401	175	147	141	124
EBIT	-530.91	-213	-337	867	708	-486
EBIT Margin	-17.41%	-6.86%	-17.73%	29.71%	25.50%	-43.90%
Effective Tax Rate	-	-	-	14.94%	14.11%	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.